Biotech Investors are Hungry for the Next Big Buyout Target
The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target. Therefore, many investors have started to search for “the next Kite” opportunity. What if we told you that some of the “top brass” in the biotechnology sector have made a move to join a company that, right now, is flying under the radar of larger investment firms?
Bayer Shakes Up R&D Unit As Busch Is On His Way Out
After confining research deals that could potentially be worth billions in November, big pharma Bayer is investigating this internally as it brings in the changes. In a huge re-structuring, Bayer reports it will be combining its pharma R&D unit under one roof and under one leader in an attempt to shake things up like its competitor European pharma Novartis did in 2016.